Publisher
Springer Science and Business Media LLC
Reference13 articles.
1. Smith MY, van Til J, DiSantostefano RL, Hauber AB, Marsh K. Quantitative benefit–risk assessment: state of the practice within industry. Therap Innovat Regulat Sci. 2021;55:415–25.
2. FDA Review of Rivaroxaban for Symptomatic PAD. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/202439Orig1s035.pdf . Accessed August 3, 2023.
3. FDA Draft Guidance on Benefit-Risk Assessment for New Drug and Biological Products. Available at https://www.fda.gov/media/152544/download . Accessed August 3, 2023
4. Marsh K, Ijzerman M, Thokala P, et al. Multiple criteria decision analysis for health care decision making–emerging good practices: report 2 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19:125–37.
5. Keeney RL, Raiffa H. Decisions with multiple objectives: preferences and value trade-offs. Cambridge, England: Cambridge University Press; 1993.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献